XML 58 R48.htm IDEA: XBRL DOCUMENT v3.25.2
STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
May 15, 2025
May 05, 2025
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Mar. 31, 2025
Feb. 21, 2025
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Number of shares issued for cash     51,203            
Number of shares issued, value     $ 395,474            
Class of warrant     1,145,928            
Exercise of warrants     $ 3,949,730          
Stock based compensation     $ 125,127          
Number of options outstanding     136,183         136,183  
Stock option, exercise price     $ 3.72           $ 3.72
Share based compensation intrinsic value     $ 0            
Share based compensation expense     0 0          
Employees [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Share based compensation expense     61,701 81,052          
Unamortized stock option expense     400,293            
Non-Employees [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Share based compensation expense     63,416 $ 154,962          
Unamortized stock option expense     $ 275,498            
Share-Based Payment Arrangement, Option [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Number of options outstanding     136,183         136,183  
Number of options issued     0 0          
Stock option, exercise price     $ 3.72         $ 3.72  
Share based compensation expense     $ 125,117 $ 236,014          
Unamortized stock option expense     $ 675,791            
Weighted average period for unamortized stock compensation (in years)     2 years 9 months 14 days            
Share-Based Payment Arrangement, Option [Member] | General and Administrative Expense [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Share based compensation expense     $ 89,523 134,769          
Share-Based Payment Arrangement, Option [Member] | Research and Development Expense [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Share based compensation expense     $ 35,594 $ 101,245          
2006 Equity Incentive Plan [Member] | Minimum [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Stock option, exercise price                 56.00
2006 Equity Incentive Plan [Member] | Maximum [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Stock option, exercise price                 70.00
2016 Equity Incentive Plan [Member] | Minimum [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Stock option, exercise price                 24.36
2016 Equity Incentive Plan [Member] | Maximum [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Stock option, exercise price                 $ 278.88
2016 Plan [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Number of additional shares granted         14,062 13,329 13,162    
Number of shares available for grant     62,412         91,371  
Series D Preferred Stock [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Conversion price $ 10.00                
Stated value $ 1,000                
Phytanix Bio [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Stock based compensation $ 10                
Phytanix Bio [Member] | Series C Preferred Stock [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Number of shares issued for cash     5,705            
Phytanix Bio [Member] | Series C-1 Preferred Stock [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Number of shares issued for cash     950,000            
Phytanix Bio [Member] | Series D Preferred Stock [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Number of shares issued for cash     20,000            
ABTI Pharma Limited [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Number of shares issued for cash       200          
Number of shares issued, value       $ 319,761          
Common Stock [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Number of shares issued for cash     51,203            
Number of shares issued, value     $ 5            
Number of reverse split shares   3,920              
Common Stock [Member] | Series C Preferred Stock [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Shares conversion 1                
Common Stock [Member] | Phytanix Bio [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Number of shares issued for cash     117,690 800,000          
Preferred Stock [Member] | Phytanix Bio [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Number of shares issued for cash       17,000          
Number of shares issued, value       $ 44,560          
Warrant [Member]                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                  
Shares issuable under warrants     3,978,000            
Warrant exercise price     $ 219.05            
Warrants outstanding, intrinsic value     $ 147,310            
Shares of warrants 719,056